Switch theme
Sign up to access all valuation multiples
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
1993
307
LTM Revenue $62.5M
LTM EBITDA $1.2M
$40.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BRAIN Biotech has a last 12-month revenue of $62.5M and a last 12-month EBITDA of $1.2M.
In the most recent fiscal year, BRAIN Biotech achieved revenue of $58.7M and an EBITDA of -$4.5M.
BRAIN Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BRAIN Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $59.4M | $58.7M | XXX | XXX | XXX |
| Gross Profit | $29.5M | $32.4M | XXX | XXX | XXX |
| Gross Margin | 50% | 55% | XXX | XXX | XXX |
| EBITDA | -$2.1M | -$4.5M | XXX | XXX | XXX |
| EBITDA Margin | -4% | -8% | XXX | XXX | XXX |
| Net Profit | -$7.1M | -$8.9M | XXX | XXX | XXX |
| Net Margin | -12% | -15% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BRAIN Biotech's stock price is EUR 2 (or $3).
BRAIN Biotech has current market cap of EUR 51.8M (or $55.6M), and EV of EUR 37.3M (or $40.1M).
See BRAIN Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $40.1M | $55.6M | XXX | XXX | XXX | XXX | $-0.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BRAIN Biotech has market cap of $55.6M and EV of $40.1M.
BRAIN Biotech's trades at 0.6x LTM EV/Revenue multiple, and 33.7x LTM EBITDA.
Analysts estimate BRAIN Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BRAIN Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $40.1M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | -15.7x | XXX | XXX | XXX |
| P/E | -5.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -6.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBRAIN Biotech's NTM/LTM revenue growth is 10%
BRAIN Biotech's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, BRAIN Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BRAIN Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BRAIN Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 114% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 6% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 72% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Borouge | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Akzo Nobel | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantium | XXX | XXX | XXX | XXX | XXX | XXX |
| DSM Firmenich | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BRAIN Biotech acquired XXX companies to date.
Last acquisition by BRAIN Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . BRAIN Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BRAIN Biotech founded? | BRAIN Biotech was founded in 1993. |
| Where is BRAIN Biotech headquartered? | BRAIN Biotech is headquartered in Germany. |
| How many employees does BRAIN Biotech have? | As of today, BRAIN Biotech has 307 employees. |
| Is BRAIN Biotech publicy listed? | Yes, BRAIN Biotech is a public company listed on ETR. |
| What is the stock symbol of BRAIN Biotech? | BRAIN Biotech trades under BNN ticker. |
| When did BRAIN Biotech go public? | BRAIN Biotech went public in 2016. |
| Who are competitors of BRAIN Biotech? | Similar companies to BRAIN Biotech include e.g. Borouge, Fertiglobe, Akzo Nobel, Avantium. |
| What is the current market cap of BRAIN Biotech? | BRAIN Biotech's current market cap is $55.6M |
| What is the current revenue of BRAIN Biotech? | BRAIN Biotech's last 12-month revenue is $62.5M. |
| What is the current EBITDA of BRAIN Biotech? | BRAIN Biotech's last 12-month EBITDA is $1.2M. |
| What is the current EV/Revenue multiple of BRAIN Biotech? | Current revenue multiple of BRAIN Biotech is 0.6x. |
| What is the current EV/EBITDA multiple of BRAIN Biotech? | Current EBITDA multiple of BRAIN Biotech is 33.7x. |
| What is the current revenue growth of BRAIN Biotech? | BRAIN Biotech revenue growth between 2023 and 2024 was -1%. |
| Is BRAIN Biotech profitable? | Yes, BRAIN Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
